FDA Approval Could Send This Biotech Stock Up 800%

Nick Martin – April 17, 2021

On February 21 last year, at the beginning of the sanitary crisis, I wrote an article on another financial paper where I called the biotech stock “CODX” an immediate buy at $3 per share.

The crisis then quickly worsened and CODX’s new test kits started selling like hot buns…

In under 90 days, CODX’s share price reached $23 and my readers locked in 700%+ profits.

Everyone has been asking me to find another stock which has the potential to go up very much as well and I believe I’ve finally found it:

The company is called Bionovate Technologies Corp [Ticker: BIIO]

There is no sector hotter than biotech at the moment. Even Warren Buffett agrees…

He just invested in Pfizer, Merck, Bristol Myers Squibb and Abbvie but the truth is that while these investments may be good for a large group like his Berkshire Hathaway, the upside potential (5-10% per year) is just not attractive for investors like us who need to hit it out of the park on one big stock.

Bionovate Technologies Corp is in my opinion a sleeping giant. A stock that could follow in the footsteps of other big biotech winners and jump 400% or more in the next months.

Despite the fact that vaccines are being rolled out, it will take years before the population is fully immunized and in the meantime COVID tests will still be critical in controlling the spread of the virus at millions of locations such as schools, businesses and airports.

BIIO’s Digital Diagnostics AG (Digid) has developed cutting-edge technology which detects COVID in real time using a smartphone connected to their 99% accurate device. The software also feeds real-time data to governments who are then able to determine the general health of an area.

The company filed for FDA approval.

Can you guess what could happen to the share price of BIIO the moment approval is granted?

The proprietary “Digid” platform on which this test is built is revolutionary and has been covered extensively by the scientific community who’s called it a “breakthrough”. The company has invented a patch which sticks to the skin and which can feed real time data to people’s smartphones. The data feed can basically be anything from COVID19 detection to the flu, sugar levels, cholesterol and much more, all in real time.

BIIO also owns patents which are the result of extensive R&D with Israel’s largest university of medicine and most prominent professors in cancer detection technologies, another field where I believe BIIO could shine, especially if they can couple cancer detection with the skin-patch tech.

BIIO is a solid investment that has potential to reach $60+ very soon.

Note: Robinhood doesn’t work to buy this stock. You’ll need TDameritrade, Schwab or another brokerage/bank account.